Viemed (VMD) VP Jerome Cambre vests RSUs, settles phantom units

Rhea-AI Filing Summary

Viemed Healthcare vice president of sales Jerome Cambre reported equity award vesting and related share movements. On January 29, 2026, 8,619 Restricted Stock Units converted into common shares and 2,873 phantom share units vested into common shares. To cover taxes from RSU vesting, the issuer withheld 2,355 common shares at a per-share value of $7.48, based on the market closing price that day. Following the reported transactions, Cambre directly held 104,088 Viemed common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cambre Jerome

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President of Sales

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/29/2026		M		8,619	A	(1)	106,443	D
Common Shares	01/29/2026		F		2,355(2)	D	$7.48(3)	104,088	D
Common Shares	01/29/2026		M		2,873	A	(4)	106,961	D
Common Shares	01/29/2026		D		2,873	D	$7.48(3)	104,088	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/29/2026		M			8,619	(5)	01/29/2027	Common Shares	8,619	$0	8,619	D
Phantom Share Units	(4)	01/29/2026		M			2,873	(6)	01/29/2027	Common Shares	2,873	$0	2,873	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.

3. Per share value is based on the market closing price of the common shares for January 29, 2026.

4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.

5. Restricted Stock Units (RSUs) granted to reporting person on January 29, 2024, which vest in three equal annual installments beginning on the first anniversary of the grant date.

6. Represents an award granted on January 29, 2024 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Viemed (VMD) Form 4 filing for Jerome Cambre report?

The Form 4 reports that Jerome Cambre, Viemed’s vice president of sales, had restricted stock units and phantom share units vest into common shares on January 29, 2026, along with share withholding to cover tax obligations tied to that vesting activity.

How many Viemed (VMD) restricted stock units vested for Jerome Cambre?

Jerome Cambre had 8,619 Restricted Stock Units vest into Viemed common shares on January 29, 2026. Each RSU represents a contingent right to receive one common share, and these units were part of a grant made on January 29, 2024 that vests in three equal annual installments.

How many Viemed (VMD) shares were withheld for Jerome Cambre’s taxes and at what price?

Viemed withheld 2,355 common shares from Jerome Cambre to satisfy tax obligations arising from RSU vesting. The per-share value used was $7.48, based on the market closing price of Viemed common shares on January 29, 2026, as described in the filing footnotes.

What are the phantom share units reported for Viemed (VMD) vice president Jerome Cambre?

The filing shows 2,873 phantom share units vesting under Viemed’s Phantom Share Unit Plan. Each phantom share is economically equivalent to one common share, with settlement for cash reported as a disposition of phantom shares and a simultaneous acquisition and disposition of underlying common shares.

How many Viemed (VMD) common shares did Jerome Cambre own after the Form 4 transactions?

After the reported January 29, 2026 transactions, Jerome Cambre directly owned 104,088 Viemed common shares. This balance reflects RSU and phantom share vesting into common shares and the dispositions, including shares withheld by the company to satisfy his related tax obligations.

How do Jerome Cambre’s Viemed (VMD) RSU and phantom grants vest over time?

Both the restricted stock units and phantom share units reported were granted on January 29, 2024 and vest in three equal annual installments. Vesting begins on the first anniversary of the grant date, meaning a portion vested on January 29, 2025 and another installment on January 29, 2026.